Last updated August 29, 2026
Key finding
The prescribing rate increased to 37.9% in VAAAHS at the end of the 12-month intervention.
This study evaluated a quality improvement intervention aimed at increasing the adoption of SGLT2 inhibitors and GLP-1 RAs in patients with Type 2 Diabetes, resulting in a significant increase in prescribing rates.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated a quality improvement intervention aimed at increasing the adoption of SGLT2 inhibitors and GLP-1 RAs in patients with Type 2 Diabetes, resulting in a significant increase in prescribing rates.
This research highlights the effectiveness of quality improvement interventions in enhancing medication prescribing practices for Type 2 Diabetes, which can lead to better patient outcomes. Increased adoption of SGLT2 inhibitors and GLP-1 RAs may improve glycemic control and reduce diabetes-related complications, making this intervention significant for healthcare providers aiming to optimize diabetes management.
The study was limited to a single healthcare system, which may affect generalizability. The effectiveness of the intervention remains unclear due to unspecified confounding factors. Only one arm was defined, limiting comparative analysis.
Published in
Publication details and source links for this paper.
Shira Y, Kathryn H, Rob H, Mandi K, Adam T, Jeremy BS. Quality Improvement Intervention to Increase Adoption of SGLT2 Inhibitors and GLP-1 RAs in Patients with Type 2 Diabetes. BMC Primary Care. 2025;26:78. doi:10.1186/s12875-025-02709-0
The prescribing rate of SGLT2 inhibitors increased to 37.9% after the intervention.
The prescribing rate of GLP-1 RAs also reached 37.9% by the end of the study.
The growth rate of prescribing in VAAAHS was significantly faster than in VISN or VA nationally (p < 0.001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Quality Improvement Intervention and Comparison of Prescribing Rates in Diabetes Medications, Prescribing Rate of GLP-1 Receptor Agonists, Rate of SGLT2 Inhibitors Prescribing.
This study contributes evidence to
Primary intervention
Quality Improvement Intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
3
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Quality Improvement Intervention → Comparison of Prescribing Rates in Diabetes Medications
Quality Improvement Intervention → Comparison of Prescribing Rates in Diabetes Medications
Quality Improvement Intervention → Prescribing Rate of GLP-1 Receptor Agonists
Quality Improvement Intervention → Prescribing Rate of GLP-1 Receptor Agonists
Quality Improvement Intervention → Rate of SGLT2 Inhibitors Prescribing
Quality Improvement Intervention → Rate of SGLT2 Inhibitors Prescribing
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Quality Improvement Intervention and Comparison of Prescribing Rates in Diabetes Medications, Quality Improvement Intervention and Prescribing Rate of GLP-1 Receptor Agonists.
This study contributes to the evidence on the following intervention-outcome relationships.
Behavioral & Lifestyle
Behavioral & Lifestyle
Curated evidence collections and hubs this study is part of.
All studies measuring Comparison of Prescribing Rates in Diabetes Medications
Measures Comparison of Prescribing Rates in Diabetes Medications as a key outcome.
All studies measuring Prescribing Rate of GLP-1 Receptor Agonists
Measures Prescribing Rate of GLP-1 Receptor Agonists as a key outcome.
All studies on Quality Improvement Intervention
Contributes to Quality Improvement Intervention evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Quality Improvement Intervention appears to improve comparison of prescribing rates in diabetes medications.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Comparison of Prescribing Rates in Diabetes Medications
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Quality Improvement Intervention appears to improve prescribing rate of glp-1 receptor agonists.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Prescribing Rate of GLP-1 Receptor Agonists
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Quality Improvement Intervention appears to improve rate of sglt2 inhibitors prescribing.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Rate of SGLT2 Inhibitors Prescribing
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
